To evaluate the inhibition of radiographic progression in joint destruction of adalimumab compared to placebo in adult Japanese subjects with rheumatoid arthritis.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00870467?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
